1. IBS Market Snap Shot
MIDDLE EAST
=SAUDI+LEBANON+KUWAIT+JORDAN

2. Middle East – Q3 04 (MAT) - Relative Market Sizes
Mkt : $ 1.56 bio; Growth MAT 04 : 10%
87
83
29
22 20 20 21
14 13
9
6 5 4 3 1
97
88
36
27
22 22 21
16
12
9
6 5 5 3 1
15%
9%
28%
33%
12% 12%
11%
16%
(1%)
0% (0%) (1%)
0%
15%
0.0
20.0
40.0
60.0
80.0
100.0
120.0
NSAID
A/H
yp
Chol
ARB
IBSAtopic
Derm
Asthm
a
A/Epil
O
steo
A/Psych
A/Virals
A/Fung
M
/R
el
A/Park
Alz
(5%)
0%
5%
10%
15%
20%
25%
30%
35%
2003
MAT 04
Grth 04

3. Middle East – Q3 04 (MAT) – IBS
Mkt : $ 21.9 mio; Growth MAT 04 : 12%
20.9%
10.0%
8.8%
5.5%
0.0%
19.6%
8.9%
9.7%
5.2%
0.5%
17.8%
9.4%
8.6%
5.9%
1.9%
0%
5%
10%
15%
20%
25%
Duspatalin Buscopan Duphalac Dulcolax Zelmac
2002 2003 MAT 04

4. Middle East - MAT Q3 04 (Pvt) - Relative Market Importance
59%
42%
47%
44%
65%
77%
57%
6% 7% 6% 7% 6% 4%
7%
19%
38%
35%
32%
12%
6%
23%
5%
3% 3% 3% 4% 3%
5%
11% 10% 9%
14% 14%
10% 10%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
Market AHD ARB Chol NSAID ATOP IBS
KSA Jordan Lebanon Kuwait UAE

5. Middle East - Q3 04 (MAT) - Zelmac
0.0% 0.0% 0.0% 0.0%
0.4%
0.0% 0.0%
0.9%
0.0%
2.7%
0.5% 0.6%
3.7%
0.0%
7.7%
0%
1%
2%
3%
4%
5%
6%
7%
8%
9%
KSA Jordan Lebanon Kuwait UAE
2002 2003 MAT 04

6. Middle East - Q3 04 (MAT) - Zelmac
0.0% 0.0% 0.0% 0.0%
0.4%
0.0% 0.0%
0.9%
0.0%
2.7%
0.5% 0.6%
3.7%
0.0%
7.7%
0%
1%
2%
3%
4%
5%
6%
7%
8%
9%
KSA Jordan Lebanon Kuwait UAE
2002 2003 MAT 04